143 related articles for article (PubMed ID: 23915075)
21. Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
Matsuo K; Machida H; Takiuchi T; Garcia-Sayre J; Yessaian AA; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):41-49. PubMed ID: 28215841
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
23. Nodal metastasis in endometrial cancer.
Willis G; Misas JE; Byrne W; Podczaski E
Eur J Gynaecol Oncol; 2011; 32(3):259-63. PubMed ID: 21797112
[TBL] [Abstract][Full Text] [Related]
24. Stage IIIA endometrial carcinoma: outcome and predictors of survival.
Bansal S; Buck AM; Herzog TJ; Deutsch I; Burke WM; Wright JD
Obstet Gynecol; 2009 Jul; 114(1):100-105. PubMed ID: 19546765
[TBL] [Abstract][Full Text] [Related]
25. Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Topfedaisi Ozkan N; Öz M; Kimyon Comert G; Firat Cuylan Z; Çoban G; Turkmen O; Erdem B; Şahin H; Akbayır Ö; Dede M; Turan AT; Celik H; Güngör T; Haberal A; Arvas M; Meydanli MM
J Gynecol Oncol; 2018 Jul; 29(4):e48. PubMed ID: 29770619
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of solid growth in endometrioid endometrial adenocarcinoma.
Akar S; Çelik ZE; Fındık S; İlhan TT; Ercan F; Çelik Ç
Int J Clin Oncol; 2020 Jan; 25(1):195-202. PubMed ID: 31452018
[TBL] [Abstract][Full Text] [Related]
27. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
28. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
29. Mucinous Proliferations of the Uterine Corpus: Comprehensive Appraisal of an Evolving Spectrum of Neoplasms.
Fadare O
Adv Anat Pathol; 2022 Sep; 29(5):275-296. PubMed ID: 35499137
[TBL] [Abstract][Full Text] [Related]
30. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
Tong SY; Lee JM; Choi YJ; Lee JK; Kim JW; Cho CH; Kim SM; Park SY; Park CY; Kim KT
Aust N Z J Obstet Gynaecol; 2012 Feb; 52(1):44-8. PubMed ID: 22188343
[TBL] [Abstract][Full Text] [Related]
31. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
Rydzewski NR; Strohl AE; Donnelly ED; Kanis MJ; Lurain JR; Nieves-Neira W; Strauss JB
Cancer; 2016 Dec; 122(23):3724-3731. PubMed ID: 27509082
[TBL] [Abstract][Full Text] [Related]
32. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.
Park JY; Nam JH; Kim YT; Kim YM; Kim JH; Kim DY; Sohn I; Lee SW; Sung CO; Kim KR
Virchows Arch; 2013 Mar; 462(3):289-96. PubMed ID: 23417747
[TBL] [Abstract][Full Text] [Related]
33. A case with three primary tumors of the ovary, endometrium and gallbladder.
Ozan H; Ozerkan K; Aker S; Bülbül M
Eur J Gynaecol Oncol; 2008; 29(5):551-3. PubMed ID: 19051835
[TBL] [Abstract][Full Text] [Related]
34. Endometrial Adenocarcinomas With Significant Mucinous Differentiation: A Characterization of Intratumoral Heterogeneity of KRAS Mutations in Mucinous and Endometrioid Histologic Components.
Jackson CL; Hang S; Hansen K; He M; Sung CJ; Quddus MR; Xiong M; Wang Y; Patel NR; Lawrence WD; Xiong J
Int J Gynecol Cancer; 2018 Feb; 28(2):241-247. PubMed ID: 29303928
[TBL] [Abstract][Full Text] [Related]
35. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
36. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
37. Pathological findings in early-stage endometrial cancer.
Zehavi S; Schneider D; Bukovsky I; Halperin R
Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
[TBL] [Abstract][Full Text] [Related]
38. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.
Brüning A; Jückstock J; Blankenstein T; Makovitzky J; Kunze S; Mylonas I
Histol Histopathol; 2010 Nov; 25(11):1447-56. PubMed ID: 20865667
[TBL] [Abstract][Full Text] [Related]
39. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
40. Impact of Mucinous Histology on the Prognosis of Stage I-III Adenocarcinomas of the Appendix: a Population-Based, Propensity Score-Matched Analysis.
Widmann B; Warschkow R; Schmied BM; Marti L; Steffen T
J Gastrointest Surg; 2016 Aug; 20(8):1493-502. PubMed ID: 27120448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
